Bone marrow mesenchymal stem cell co-adjuvant therapy with albendazole for managing Toxocara vitulorum-rat model

Research (Published online: 08-02-2021)

6. Bone marrow mesenchymal stem cell co-adjuvant therapy with albendazole for managing Toxocara vitulorum-rat model

Faten A. M. Abo-Aziza, Abdel Kader A. Zaki, Ahmed I. Alajaji and Saleh M. Al barrak

Veterinary World, 14(2): 347-363

Faten A. M. Abo-Aziza: Department of Parasitology and Animal Diseases, Veterinary Research Division, National Research Centre, Cairo, Egypt.

Abdel Kader A. Zaki: Department of Physiology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt; Department of Veterinary Medicine, College of Agriculture and Veterinary Medicine, Qassim University, Buraydah, Saudi Arabia.

Ahmed I. Alajaji: Department of Veterinary Medicine, College of Agriculture and Veterinary Medicine, Qassim University, Buraydah, Saudi Arabia.

Saleh M. Al barrak: Department of Veterinary Medicine, College of Agriculture and Veterinary Medicine, Qassim University, Buraydah, Saudi Arabia.

doi: www.doi.org/10.14202/vetworld.2021.347-363

Share this article on [Facebook] [LinkedIn]

Article history: Received: 09-09-2020, Accepted: 28-12-2020, Published online: 08-02-2021

Corresponding author: Faten A. M. Abo-Aziza

E-mail: faten.aboaziza@gmail.com

Citation: Abo-Aziza FAM, Zaki AA, Alajaji AI, Albarrak SM (2021) Bone marrow mesenchymal stem cell co-adjuvant therapy with albendazole for managing Toxocara vitulorum-rat model, Veterinary World, 14(2): 347-363.

Abstract

Background and Aim: Toxocara vitulorum is a bovine intestinal nematode. Immune pictures following infection are conflicting and stopping anthelmintic albendazole treatment recording reversed liver abnormalities. The purpose of this work was to evaluate the therapeutic potential of bone marrow mesenchymal stem cells (BMMSCs) therapy, subsequent to albendazole administration in rats infected with T. vitulorum.

Materials and Methods: The ultrasonographic and histopathological examinations as well as serum liver enzymes activity and the kinetics of recovery were investigated. The correlation of cell-mediated and humoral immune pictures was assessed by assaying immunoglobulins, splenocytes viability, phagocytic index, and Th1/Th2 cytokines.

Results: The cultured BMMSCs counting were 4.21×10⁴ cells/cm² with 96.03% viability. Flow-cytometric analysis indicated positive CD90 (82%), CD105 (79%) and negative CD34 (0.37%), CD45 (0.42%), attesting to the suitability of the isolated BMMSCs for use in therapy. Transplantation of BMMSCs after albendazole administration significantly reduced the release of liver enzymes (p<0.05) indicating liver cellularity improvement. The ultrasonographic, macroscopic, and histopathological findings confirmed the biochemical results. Significant elevation in the levels of tumor necrosis factor (TNF)-α and interferon (INF)-γ with a decline in interleukin (IL)-4 was observed in the untreated model (p<0.05). However, albendazole treatment followed by BMMSCs therapy significantly lowered the release of TNF-α and INF-γ, associated with significant production of IL-4 and IL-10 (p<0.05).

Conclusion: The final results indicated that the liver functions, histopathological findings, and immune parameters were aggravated after experimental T. vitulorum infection. Albendazole treatment followed by BMMSCs therapy was found to assist in regeneration of injured hepatic tissue. Besides, it appeared to modulate host defensive immune responses against T. vitulorum antigens. This work could define more clearly the events that manipulate the host immune, histopathological, and biochemical responses to minimize obstacles in using stem cell therapy in animal toxocariosis.

Keywords: albendazole, bone marrow mesenchymal stem cells, cell therapy, rat, Toxocara vitulorum.